scholarly journals Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

2018 ◽  
Vol 2 (12) ◽  
pp. 1386-1392 ◽  
Author(s):  
Kristina Drott ◽  
Hans Hagberg ◽  
Karin Papworth ◽  
Thomas Relander ◽  
Mats Jerkeman
Keyword(s):  
Histone Deacetylase Inhibitor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Promising Strategy ◽  
Line Therapy ◽  
Deacetylase Inhibitor ◽  
Key Points

Key Points This trial evaluates addition of the histone deacetylase inhibitor valproate to standard R-CHOP therapy in DLBCL. Addition of valproate to R-CHOP is a promising strategy in DLBCL, but auditory side effects warrant monitoring.

scholarly journals Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study

2020 ◽  
Vol 38 (3) ◽  
pp. 318-325
Author(s):  
Michael R. Clausen ◽  
Sinna P. Ulrichsen ◽  
Maja B. Juul ◽  
Christian B. Poulsen ◽  
Brian Iversen ◽  
...  
Keyword(s):  
Cohort Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
B Cell Lymphoma ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Large B Cell

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

2007 ◽  
Vol 15 (7) ◽  
pp. 877-884 ◽  
Author(s):  
Ulrich J. M. Mey ◽  
Anna Maier ◽  
Ingo G. H. Schmidt-Wolf ◽  
Carsten Ziske ◽  
Helmut Forstbauer ◽  
...  
Keyword(s):  
Elderly Patients ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
First Line ◽  
First Line Therapy ◽  
Large B Cell Lymphoma ◽  
Line Therapy ◽  
Dose Dense ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document